Learning community for ASCVD
Welcome to the inaugural edition of the VESL Wall. Each month we will feature a few articles recently posted in the VESL community and highlight their clinical impact and Canadian perspective.
The first issue of the VESL Wall, including a video summary by Dr. Liam Brunham, was sent to all VESL members by email on March 1, and can be accessed online here.
We’re pleased to announce the launch of a new initiative called VESL (Virtual Engagement Social Learning), an online learning community for Canadian healthcare professionals with an interest in atherosclerotic cardiovascular disease.
VESL will foster open scientific discussions through online forums, webinars and micro-learning objects, to sustain ongoing connection anchored in scientific discovery and expert insight. It is our hope that this enhanced collaboration will advance understanding in this field and support the highest level of care for patients in Canada.
Members of VESL will receive a weekly email digest with a summary of newly-released scientific articles from VESL members, curated content from sources identified by the VESL faculty, as well as periodic learning opportunities including structured questions to initiate forum discussions, and polling questions to augment community discussions.
LegitiMed will be managing this virtual community residing on Sosido (www.sosido.com).
We are interested in a full exchange of ideas around this subject. So, if you know others who would be interested in participating in the VESL community, we welcome your referrals/recommendations.
We thank Novartis Canada for their support of this initiative.
The VESL community is designed for the scientific exchange of information between Healthcare Professionals and is made possible with financial support from Novartis Canada. Novartis does not itself monitor the discussions. However, a third-party service provider does review the discussions only for the purpose of identifying any potential AE discussion. This review is required since as a drug manufacturer, Novartis has a regulatory obligation to report any AE that (directly or indirectly) comes to their attention. The third-party will only report the potential AE discussion and will include contact information. Should your post be reported to patient safety, you will be contacted by the third-party service provider to determine if you would like Novartis patient safety to contact you for more details.
